KDM6B and neuroblastoma: To correlate the clinical relevance of target genes of KDM6B inhibition, we identified a 149-gene signature (Supplementary Table 7) that was commonly downregulated by GSK-J4 in BE2C and three other neuroblastoma cell lines (IMR5, LAN5, and SK-N-FI)43.